Estrella Immunopharma Inc (ESLA)

Currency in USD
1.407
-0.123(-8.04%)
Closed·
1.400-0.007(-0.46%)
·
ESLA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
1.3901.550
52 wk Range
0.7803.150
Key Statistics
Prev. Close
1.53
Open
1.5
Day's Range
1.39-1.55
52 wk Range
0.78-3.15
Volume
18.86K
Average Volume (3m)
114.43K
1-Year Change
24.5133%
Book Value / Share
-0.27
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ESLA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to drop this year

Estrella Immunopharma Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate

Earnings

Latest Release
18-03-2026
EPS / Forecast
-0.02 / --
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

ESLA Income Statement

Compare ESLA to Peers and Sector

Metrics to compare
ESLA
Peers
Sector
Relationship
P/E Ratio
−5.0x−4.0x−0.5x
PEG Ratio
0.11−0.170.00
Price/Book
−6.3x3.0x2.6x
Price / LTM Sales
-4.8x3.3x
Upside (Analyst Target)
-125.6%47.1%
Fair Value Upside
Unlock−13.8%6.2%Unlock

Estrella Immunopharma, Inc., a clinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company’s lead product candidate is EB103, which is in Phase I/II clinical trial, for the treatment of diffuse large B-cell lymphoma; EB104, which is in pre-clinical trial, to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia; and EB201, which is in pre-clinical trial, for the treatment of systemic lupus erythematosus. It offers ARTEMIS, a cell receptor platform to develop and commercialize T-cell therapies targeting CD19 and CD22 for the treatment of hematologic malignancies. It has a collaborative agreement with Eureka and Imugene Limited for the development of solid tumor treatments using Imugene’s product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. was founded in 2006 and is headquartered in EmeryVille, California. Estrella Immunopharma, Inc. is a subsidiary of Eureka Therapeutics, Inc.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
580.81K1.36%888.65K
Other Institutional Investors
24.31M56.99%37.20M
Public Companies & Retail Investors
17.77M41.65%27.19M
Total
42.67M100.00%65.28M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
Vanguard Index Funds - Vanguard Total Stock Market ETF0.63%2,68,005410
Vanguard Index Funds - Vanguard Extended Market ETF0.27%1,14,464175

FAQ

What Is the Estrella Immunopharma (ESLA) Share Price Today?

The Estrella Immunopharma share price today is 1.407.

What is the current Estrella Immunopharma (ESLA) share price and day range?

As of 05-05-2026, the Estrella Immunopharma share price is 1.407, with a previous close of 1.530. The share price has ranged from 1.390 to 1.550 today, while the 52-week range spans from 0.780 to 3.150.

What Is the Estrella Immunopharma Market Cap?

As of today, Estrella Immunopharma market cap is 65.280M.

What Is the Estrella Immunopharma (ESLA) Share Price Target?

The average 12-month share price target for Estrella Immunopharma is 12.000, with a high estimate of 12 and a low estimate of 12. 0 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +752.88% Upside potential.

What Is Estrella Immunopharma's Earnings Per Share (TTM)?

The Estrella Immunopharma EPS (TTM) is -0.355.

From a Technical Analysis Perspective, Is ESLA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

What Stock Exchange Does Estrella Immunopharma Trade On?

Estrella Immunopharma is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Estrella Immunopharma?

The stock symbol for Estrella Immunopharma is "ESLA."

How Many Times Has Estrella Immunopharma Stock Split?

Estrella Immunopharma has split 0 times.

What Is the ESLA Premarket Price?

ESLA's last pre-market stock price is 1.500. The pre-market share volume is 230.000, and the stock has changed by -0.030, or -1.960%.

What Is the ESLA After Hours Price?

ESLA's last after hours stock price is 1.400, the stock has changed by -0.007, or -0.460%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.